Skip to content

Sedation Level on Machine Learning With Electroencephalogram in Painless Gastroenteroscopy Patients

Sedation Level Estimation Based on Machine Learning of Quantitative Occipital Electroencephalogram Features in Gastroenteroscopy Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05545397
Enrollment
50
Registered
2022-09-19
Start date
2022-09-15
Completion date
2022-12-31
Last updated
2022-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastritis

Keywords

Deep Sedation, Machine learning, EEG characheristics;, Painless gastroscopy

Brief summary

Painless endoscopy technology can make patients comfortable under anesthesia, but because of the painless inside.The diagnosis and treatment time of endoscopic examination is short, and the transport is fast. Anesthesia related wind such as deep breathing depression and hypoxemia will occurRisks.Eeg depth monitoring can assist anesthesiologists to evaluate the depth of anesthesia and reduce the risk. Artificial intelligence is adopted.There are few reports on the evaluation of anesthesia depth and drug dosage by electroencephalogram (EEG) monitoring in outpatient patients with painless gastroenteroscopy.

Detailed description

1.examination, and establish brainClassification model of electrogram and sedation depth;2. The EEG characteristics, basic information and propofol were administered to all patients.The dose model of propofol painless gastroenteroscopy was established by machine learning to guide anesthesia Drug use;3. Evaluate the time and space complexity of the model, build the model, and assist the anesthesiologist to individualize the patient Chemical, safe and comfortable management.

Interventions

DRUGPropofol

And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG

DEVICEEEG montior

And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG

Sponsors

General Hospital of Ningxia Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Painless gastroenteroscopy patients 2. ASA classification is Ⅰ-Ⅱ 3. Patients who are willing to cooperate 4. No schizophrenia,epilepsy and other neurological diseases

Exclusion criteria

1. allergic to propofol 2. Patients who are unwilling to cooperate 3. Patients with psychiatric disorders 4. Patients using sedative drugs for a long time 5. Patients with neuropsychiatric disorders 6. Patients with severe heart, liver, kidney and respiratory diseases

Design outcomes

Primary

MeasureTime frameDescription
Electroencephalogram featuresduring gastroenteroscopy procedureTime feature;frequency feature;Entropy
Propofol dosageduring gastroenteroscopy procedurefrom awake to sedation in painless gastroenteroscopy

Secondary

MeasureTime frameDescription
physiological parameter(oxygen saturation )during gastroenteroscopy procedurefrom awake to sedation in painless gastroenteroscopy with ECG monitor
time parameter (Arousal times)during endoscopywith monitor and Anesthesiologist's record
success rate of once endoscopyduring endoscopywith monitor and Anesthesiologist's record
physiological parameter(blood pressure )during gastroenteroscopy procedurefrom awake to sedation in painless gastroenteroscopy with ECG monitor
Endoscopist satisfaction by questionnaireduring endoscopywith monitor and Anesthesiologist's record
vasoactive drugsduring endoscopywith monitor and Anesthesiologist's record
Incidence of hypoxemiaduring endoscopywith monitor and Anesthesiologist's record
physiological parameter(heart rate )during gastroenteroscopy procedurefrom awake to sedation in painless gastroenteroscopy with ECG monitor

Countries

China

Contacts

Primary ContactHuiwen Zhang
zhanghuiwen1128@163.com18709500998
Backup ContactZhenghong Zhao
592068802@qq.com13519576995

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026